Dr Diane Mahoney Uncovers Health Disparities Among Black, Hispanic Ovarian Cancer Survivors
July 23rd 2024Diane Mahoney, PhD, DNP, FNP-BC, WHNP-BC, APRN, discusses her study on how social determinants of health impact the health perceptions of Black and Hispanic ovarian cancer survivors, highlighting significant health disparities.
Read More
In LBCL, Barriers to CAR T Remain: SDOH and More
July 23rd 2024The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.
Read More
Patients With Intellectual Disabilities Face Distinct Challenges in COPD, Asthma Care
July 22nd 2024Patients with intellectual disabilities experience inconsistent chronic obstructive pulmonary disease (COPD) consultations and higher rates of antibiotic prescriptions for asthma, highlighting the need for improved and tailored primary care management.
Read More
Diagnosing and Managing Scarring Alopecia in Adolescents
July 22nd 2024Marissa Joseph, MD, MSc, FRCPC, medical director at Women’s College Hospital in Toronto, Ontario, Canada, highlighted cases from her practice to illustrate the recommended approach to scarring inflammatory scalp dermatosis in adolescents at the Society for Pediatric Dermatology Annual Meeting.
Read More
Dr Mark Bleackley Addresses Lack of Pharmacotherapies in OSA, Need for IHL-42X
July 22nd 2024Mark Bleackley, PhD, chief scientific officer of Incannex, discusses in further detail the need for a pharmacotherapy like IHL-42X in obstructive sleep apnea (OSA) and the medication's underlying mechanisms.
Read More
Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC
July 22nd 2024Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
Read More
Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa
July 22nd 2024Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails that is caused by mutations in the COL7A1 gene.
Read More
Understanding Coverage, Financing, and Future Trends of Gene Therapy in Employer Health Plans
July 21st 2024The Greater Philadelphia Business Coalition on Health webinar series provided an in-depth framework for the advantages of including cell and gene therapy coverage in employer health plans, as well as the challenges brought by manufacturing complexities and the need to address accessibility to treatment.
Read More